Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 M versus AMINOSYN II 4 25 W ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: AMINOSYN 3 5 M versus AMINOSYN II 4 25 W ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10 IN PLASTIC CONTAINER.
AMINOSYN 3.5% M vs AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% M is a crystalline amino acid solution providing essential and nonessential amino acids for protein synthesis, tissue repair, and maintenance of nitrogen balance. It acts as a substrate for anabolic processes and helps correct negative nitrogen balance.
Aminogen (amino acids) provide substrate for protein synthesis; dextrose provides caloric energy; electrolytes maintain acid-base and fluid balance; phosphate is essential for cellular metabolism and buffering.
Intravenous infusion; typical adult dose: 1 to 1.5 g amino acids/kg/day (equivalent to 28.6 to 42.9 mL/kg/day of 3.5% solution). Administer via central or peripheral line at a rate not exceeding 0.5 g amino acids/kg/hour.
Intravenous infusion; typical adult dose: 1-1.5 g amino acids/kg/day, with dextrose providing 10% final concentration. Adjusted to meet protein and caloric needs.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is typically 0.5-2 hours in patients with normal renal and metabolic function, reflecting rapid uptake and metabolism by tissues. In hepatic or renal impairment, half-life may be prolonged due to decreased clearance.
Amino acids have a terminal elimination half-life of approximately 1.5–2 hours in healthy adults, reflecting rapid metabolic clearance. In renal impairment, half-life may be prolonged due to accumulation of nitrogenous waste.
Amino acids in Aminosyn 3.5% M are primarily eliminated via metabolism (utilization for protein synthesis, energy, and other metabolic pathways). Minimal amounts are excreted unchanged in urine (less than 5% of infused amino acids) via glomerular filtration. There is no significant biliary or fecal elimination.
The components of AMINOSYN II (amino acids) and dextrose are primarily metabolized; excess nitrogen is excreted renally as urea. Dextrose is completely oxidized. Electrolytes are excreted mainly renally. Biliary/fecal elimination is negligible for amino acids and dextrose (<2%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution